Lyra Therapeutics Inc
LYRA30.449USD
+25.519+517.63%
Market hours （ET）Quotes delayed by 15 min
2.01BMarket Cap
LossP/E TTM
More Details of Lyra Therapeutics Inc Company
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
Company Info
Company codeLYRA
Company nameLyra Therapeutics Inc
IPO dateMay 01, 2020
Founded at2005
CEODr. Maria Palasis, Ph.D.
Number of employees30
Security typeOrdinary Share
Fiscal year-endMay 01
Address480 Arsenal Way
CityWATERTOWN
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02472
Phone16173734600
Websitehttps://lyratherapeutics.com/
Company codeLYRA
IPO dateMay 01, 2020
Founded at2005
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Harlan W. Waksal, M.D.
Dr. Harlan W. Waksal, M.D.
Executive Chair and Chairperson of the Board
Executive Chair and Chairperson of the Board
10.74K
--
Dr. Nancy L. Snyderman, M.D.
Dr. Nancy L. Snyderman, M.D.
Independent Director
Independent Director
--
--
Dr. Maria Palasis, Ph.D.
Dr. Maria Palasis, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-100.00%
Dr. Richard Nieman, M.D.
Dr. Richard Nieman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. James R (Jim) Tobin
Mr. James R (Jim) Tobin
Lead Independent Director
Lead Independent Director
--
--
Ms. C. Ann Merrifield
Ms. C. Ann Merrifield
Independent Director
Independent Director
--
--
Mr. W. Bradford Smith
Mr. W. Bradford Smith
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Harlan W. Waksal, M.D.
Dr. Harlan W. Waksal, M.D.
Executive Chair and Chairperson of the Board
Executive Chair and Chairperson of the Board
10.74K
--
Dr. Nancy L. Snyderman, M.D.
Dr. Nancy L. Snyderman, M.D.
Independent Director
Independent Director
--
--
Dr. Maria Palasis, Ph.D.
Dr. Maria Palasis, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-100.00%
Dr. Richard Nieman, M.D.
Dr. Richard Nieman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. James R (Jim) Tobin
Mr. James R (Jim) Tobin
Lead Independent Director
Lead Independent Director
--
--
Ms. C. Ann Merrifield
Ms. C. Ann Merrifield
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Fri, May 16
Update time: Fri, May 16
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Perceptive Advisors LLC
19.25%
North Bridge Venture Partners
8.89%
BlackRock Institutional Trust Company, N.A.
4.53%
The Vanguard Group, Inc.
2.66%
Samsara BioCapital, LLC
2.10%
Other
62.57%
Shareholder Statistics
Shareholder
Proportion
Perceptive Advisors LLC
19.25%
North Bridge Venture Partners
8.89%
BlackRock Institutional Trust Company, N.A.
4.53%
The Vanguard Group, Inc.
2.66%
Samsara BioCapital, LLC
2.10%
Other
62.57%
Type
Shareholder
Proportion
Private Equity
19.25%
Venture Capital
10.98%
Investment Advisor
6.77%
Investment Advisor/Hedge Fund
6.14%
Hedge Fund
4.27%
Research Firm
0.88%
Individual Investor
0.83%
Pension Fund
0.24%
Bank and Trust
0.08%
Other
50.56%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
166
33.99M
51.29%
-25.72M
2024Q4
169
34.27M
52.36%
-23.86M
2024Q3
170
41.74M
67.36%
-17.33M
2024Q2
155
41.35M
70.46%
-15.27M
2024Q1
137
54.47M
94.92%
+4.29M
2023Q4
113
50.90M
93.69%
+8.93M
2023Q3
96
40.42M
84.31%
-314.10K
2023Q2
103
42.33M
88.17%
+11.26M
2023Q1
124
25.98M
81.63%
-890.12K
2022Q4
126
26.32M
82.72%
+975.89K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Perceptive Advisors LLC
12.76M
19.36%
--
--
Dec 31, 2024
North Bridge Venture Partners
5.89M
8.94%
--
--
Feb 28, 2025
BlackRock Institutional Trust Company, N.A.
3.08M
4.68%
+98.60K
+3.31%
Dec 31, 2024
The Vanguard Group, Inc.
1.79M
2.71%
+8.16K
+0.46%
Dec 31, 2024
Samsara BioCapital, LLC
1.97M
2.98%
-814.57K
-29.30%
Dec 31, 2024
Ikarian Capital LLC
1.06M
1.61%
+1.32K
+0.12%
Dec 31, 2024
Geode Capital Management, L.L.C.
885.97K
1.34%
+117.58K
+15.30%
Dec 31, 2024
Nantahala Capital Management, LLC
628.07K
0.95%
+628.07K
--
Sep 30, 2024
Two Sigma Investments, LP
595.50K
0.9%
-147.35K
-19.84%
Dec 31, 2024
Waksal (Harlan W)
536.97K
0.82%
+275.00K
+104.98%
Feb 28, 2025
View more
Related ETFs
Update time: 5 hours ago
Update time: 5 hours ago
Name
Proportion
ProShares Hedge Replication ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Growth ETF
0%
View more
ProShares Hedge Replication ETF
Proportion0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
